GSK Dodges Putative Class Claims Over Avandia Payments

Law360, Philadelphia (July 12, 2013, 4:15 PM EDT) -- A Pennsylvania federal judge on Wednesday tossed out four putative class actions against GlaxoSmithKline PLC, in which the plaintiffs sought refunds of the co-pays and other money they spent on purchasing the diabetes treatment drug Avandia.

U.S. District Judge Cynthia Rufe found that each of the four suits — which individually asserted claims under California, New Jersey, New York and Pennsylvania law — failed to demonstrate that the plaintiffs had been harmed by the pharmaceutical giant’s marketing efforts.

The judge dismissed all four suits with prejudice....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.